Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)
- DOI
- 10.1016/j.lungcan.2017.09.007
- Published
- 2017-11
- Container
- Lung Cancer
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.lungcan.2017.09.007,
title = {Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)},
author = {David R. Spigel and Mark S. Rubin and Victor G. Gian and Dianna L. Shipley and Howard A. Burris and Rebecca A. Kosloff and Kent C. Shih and Raven Quinn and F. Anthony Greco and John D. Hainsworth},
year = {2017},
journal = {Lung Cancer},
doi = {10.1016/j.lungcan.2017.09.007},
url = {https://doi.org/10.1016/j.lungcan.2017.09.007}
}RIS
TY - JOUR TI - Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI) AU - David R. Spigel AU - Mark S. Rubin AU - Victor G. Gian AU - Dianna L. Shipley AU - Howard A. Burris AU - Rebecca A. Kosloff AU - Kent C. Shih AU - Raven Quinn AU - F. Anthony Greco AU - John D. Hainsworth PY - 2017 JO - Lung Cancer DO - 10.1016/j.lungcan.2017.09.007 UR - https://doi.org/10.1016/j.lungcan.2017.09.007 ER -
APA
Spigel, D. R., Rubin, M. S., Gian, V. G., Shipley, D. L., Burris, H. A., Kosloff, R. A., Shih, K. C., Quinn, R., Greco, F. A., & Hainsworth, J. D. (2017). Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). Lung Cancer. https://doi.org/10.1016/j.lungcan.2017.09.007
Source records
- crossref · retrieved 2026-09-26T21:42:47.598Z